Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients.

Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA.

Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):27-36. Erratum in: Pharmacoepidemiol Drug Saf. 2008 Jul;17(7):751.

PMID:
17944002
2.

Does simvastatin cause more myotoxicity compared with other statins?

Backes JM, Howard PA, Ruisinger JF, Moriarty PM.

Ann Pharmacother. 2009 Dec;43(12):2012-20. doi: 10.1345/aph.1M410. Epub 2009 Nov 17. Review.

PMID:
19920157
3.

Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.

Neuvonen PJ, Backman JT, Niemi M.

Clin Pharmacokinet. 2008;47(7):463-74. Review.

PMID:
18563955
4.

A clinical review of statins and cancer: helpful or harmful?

Gonyeau MJ, Yuen DW.

Pharmacotherapy. 2010 Feb;30(2):177-94. doi: 10.1592/phco.30.2.177. Review.

PMID:
20099992
5.

Statin-associated memory loss: analysis of 60 case reports and review of the literature.

Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM.

Pharmacotherapy. 2003 Jul;23(7):871-80. Review.

PMID:
12885101
6.

Statin use and cancer risk: a comprehensive review.

Boudreau DM, Yu O, Johnson J.

Expert Opin Drug Saf. 2010 Jul;9(4):603-21. doi: 10.1517/14740331003662620. Review.

7.

Statins as a potential risk factor for autoimmune diseases: a case report and review.

John SG, Thorn J, Sobonya R.

Am J Ther. 2014 Jul-Aug;21(4):e94-6. doi: 10.1097/MJT.0b013e31828e5bfb. Review.

PMID:
23782756
8.

Statin use and cancer risk: an epidemiologic review.

Friis S, Olsen JH.

Cancer Invest. 2006 Jun-Jul;24(4):413-24. Review.

PMID:
16777695
9.

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Lennernäs H, Fager G.

Clin Pharmacokinet. 1997 May;32(5):403-25. Review.

PMID:
9160173
10.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

11.

Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.

Grundy SM.

Am J Cardiol. 1998 Feb 26;81(4A):1B-6B. Review. No abstract available.

PMID:
9526806
12.
13.

Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened.

Friedman GD, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA.

Cancer Causes Control. 2009 Dec;20(10):1821-35. doi: 10.1007/s10552-009-9375-2. Review.

Supplemental Content

Support Center